LONDON, May 10: GlaxoSmithKline will take its 2.6 billion dollars bid for long-time partner Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the US biotech group’s board. The decision to go hostile with the $13-a-share cash tender offer sets up GSK for a potentially lengthy battle with those Human Genome investors who believe it is not offering enough. (agencies)
Trending Now
E-Paper
Follow our WhatsApp channel